Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983966 | 0.84 | NOTUM (0.47) | SMN1; SMN2NOTUMTSHRKMT2AMEN1 | |
| SCHEMBL29092593 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2NOTUMTSHRKMT2AMEN1 | |
| SCHEMBL30866830 | 0.76 | TSHR (0.59) | SMN1; SMN2TSHRKMT2AMEN1LMNA | |
| SCHEMBL27754978 | 0.76 | MEN1 (0.47) | SMN1; SMN2NOTUMTSHRKMT2AMEN1 | |
| SCHEMBL5261945 | 0.76 | TSHR (0.59) | SMN1; SMN2TSHRKMT2AMEN1LMNA | |
| SCHEMBL8861369 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2NOTUMTSHRKMT2AMEN1 | |
| SCHEMBL5263502 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2NOTUMTSHRKMT2AMEN1 | |
| SCHEMBL28965840 | 0.74 | TSHR (0.50) | SMN1; SMN2NOTUMTSHRKMT2AMEN1 | |
| SCHEMBL27559695 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2NOTUMTSHRKMT2AMEN1 | |
| SCHEMBL6769554 | 0.73 | MEN1 (0.46) | NOTUMTSHRKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019623-B1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2018-11-28 | — | — | EP | disclosed |
| US-9630923-B2 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | EUTICALS SPA (IT) | 2017-04-25 | — | — | US | disclosed |
| EP-3019623-A1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | Euticals S.P.A. (IT) | 2016-05-18 | — | — | EP | disclosed |
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | AMRI ITALY S.R.L. (IT) | 2016-05-05 | — | — | US | disclosed |
| WO-2015004015-A1 | BIOCATALYZED SYNTHESIS OF THE OPTICALLY PURE (R) AND (S) 3-METHYL-1,2,3,4-TETRAHYDROQUINOLINE AND THEIR USE AS CHIRAL SYNTHONS FOR THE PREPARATION OF THE ANTITHROMBOTIC (21R)- AND (21S)-ARGATROBAN | EUTICALS SPA (IT) | 2015-01-15 | — | — | WO | disclosed |
| EP-2824187-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombotic (21R)- and (21S)-argatroban | Euticals S.P.A. (IT) | 2015-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122303-A1 | Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatroban | CYP2S1, PRMT3, ARGLU1 | SMN1; SMN2 3199/4885NOTUM 2291/4885TSHR 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.